Nexxt Spine, LLC., confident with four new 510(k) product clearances this year, is investing to expand its sales team. The company will also double the size of its Noblesvile, Indiana, headquarters and manufacturing facility later this year. The newly cleared devices include several additions to the Nexxt Matrixx line, a series of 3D-printed titanium interbody fusion devices, such as a standalone cervical device. Additionally, the company received clearance for a new device in the TrellOss™ line marketed by Zimmer Biomet, called TrellOss™-L MPF.
Nexxt Spine Builds Out National Sales Team

After helping to double NuVasive, Inc.’s revenue by managing the company’s Australia and New Zealand region, Keith Cunnion was hired by Nexxt Spine, LLC. Cunnion will head the company’s Eastern U.S. Region as the Regional Sales Manager. He has also previously worked with Amniox and Amedica Corporation.
Another addition to the sales management team is Clay Williams, who will head the Central U.S. Region. His previous experience in orthopedics and spine products will aid him in his new role. He has worked for Stryker Corporation, Amedica, and most recently NuVasive. He has received numerous awards for his sales record, including the Quota Buster, Manager of the Year Sales Director Breakout Performance, and the Service Line Partnership Awards.
Nexxt Spine, LLC. is a privately held medical device manufacturer that specializes in spine devices. The company manufactures all of its own devices.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.